Wird geladen...

Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models. The optimal therapeutic dose of sirolimus is not yet defined. Here...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Canaud, G., Knebelmann, B., Harris, P. C., Vrtovsnik, F., Correas, J. M., Pallet, N., Heyer, C. M., Letavernier, E., Bienaimé, F., Thervet, E., Martinez, F., Terzi, F., Legendre, C.
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	2010
Schlagworte:	Article
Online Zugang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3697013/ https://ncbi.nlm.nih.gov/pubmed/20642692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-6143.2010.03152.x
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?

Ähnliche Einträge